Citations

Clear

16281 citation(s) found for "Yu, David".

Influence of artificial intelligence on the diagnostic performance of endoscopists in the assessment of Barrett’s esophagus: a tandem randomized and video trial
Meinikheim, M. , Mendel, Robert , Scheppach, Markus W. , Nagl, Sandra , Schnoy, Elisabeth , Römmele, Christoph , Schulz, Dominik , Schlottmann, J., Prinz, Friederike, Rauber, David , Rückert, Tobias, Parsa, Nasim , Messmann, Helmut , Ebigbo, Alanna , Meinikheim, Michael , Römmele, Christoph , Matsumura, Tomoaki , Palm, Christoph , Probst, Andreas , Muzalyova, Anna , Fernández‐Esparrach, Glòria , Byrne, Michael F.

Mayo Clinic

Endoscopy | March 29, 2024 | Volume: 56 | Issue: 09 | Pages: 641-649

10.1055/a-2296-5696 | PMID 38547927 Get It

Abstract Background This study evaluated the effect of an artificial intelligence (AI)-based clinical decision support system on the performance and diagnostic confidence of endoscopists in their assessment of Barrett’s esophagus (BE). Methods 96 standardized endoscopy videos were assessed by 22 endoscopists with varying degrees of BE experience from 12 centers. Assessment was randomized into two video sets: group A (review first without AI and second with AI) and group B (review first with AI and second without AI). Endoscopists were required to evaluate each video for the presence of Barrett’s esophagus-related neoplasia (BERN) and then decide on a spot for a targeted biopsy. After the second assessment, they were allowed to change their clinical decision and confidence level. Results AI had a stand-alone sensitivity, specificity, and accuracy of 92.2%, 68.9%, and 81.3%, respectively. Without AI, BE experts had an overall sensitivity, specificity, and accuracy of 83.3%, 58.1%, and 71.5%, respectively. With AI, BE nonexperts showed a significant improvement in sensitivity and specificity when videos were assessed a second time with AI (sensitivity 69.8% [95%CI 65.2%–74.2%] to 78.0% [95%CI 74.0%–82.0%]; specificity 67.3% [95%CI 62.5%–72.2%] to 72.7% [95%CI 68.2%–77.3%]). In addition, the diagnostic confidence of BE nonexperts improved significantly with AI. Conclusion BE nonexperts benefitted significantly from additional AI. BE experts and nonexperts remained significantly below the stand-alone performance of AI, suggesting that there may be other factors influencing endoscopists’ decisions to follow or discard AI advice.
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810
Appleman, Leonard J. , Kim, Se Eun , Harris, Wayne , Pal, Sumanta K. , Pins, Michael R., Kolesar, Jill , Agarwal, Neeraj , Vaena, Daniel A. , Ryan, Christopher W. , Hashmi, Mehmood, Costello, Brian A. , Cella, David , DiPaola, Robert S. , Parikh, Rahul A , Vaena, Daniel A , Costello, Brian A , Cella, David , Dutcher, Janice P. , Haas, Naomi B , Wagner, Lynne , Agarwal, Archana M , Appleman, Leonard , Wagner, Lynne I. , Carducci, Michael A.

Mayo Clinic

Journal of Clinical Oncology | March 28, 2024 | Volume: 42 | Issue: 17 | Pages: 2061-2070

10.1200/jco.23.01544 | PMID 38531002 Get It

PURPOSE Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular endothelial growth factor receptor and other kinases that improves progression-free survival in patients with metastatic RCC (mRCC). We conducted a randomized, double-blind, placebo-controlled multicenter study to test whether pazopanib would improve disease-free survival (DFS) in patients with mRCC rendered NED after metastasectomy. PATIENTS AND METHODS Patients with NED after metastasectomy were randomly assigned 1:1 to receive pazopanib 800 mg once daily versus placebo for 52 weeks. The study was designed to observe an improvement in DFS from 25% to 45% with pazopanib at 3 years, corresponding to 42% reduction in the DFS event rate. RESULTS From August 2012 to July 2017, 129 patients were enrolled. The study was unblinded after 83 DFS events (92% information). The study did not meet its primary end point. An updated analysis at 60.5-month median follow-up from random assignment (95% CI, 59.3 to 71.0) showed that the 3-year DFS was 27.4% (95% CI, 17.9 to 41.7) for pazopanib and 21.9% (95% CI, 13.3 to 36.2) for placebo. Hazard ratio (HR) for DFS was 0.90 ([95% CI, 0.60 to 1.34]; Pone-sided = .29) in favor of pazopanib. Three-year overall survival (OS) was 81.9% (95% CI, 72.7 to 92.2) for pazopanib and 91.4% (95% CI, 84.4 to 98.9) for placebo. The HR for OS was 2.55 (95% CI, 1.23 to 5.27) in favor of placebo ( Ptwo-sided = .012). Health-related quality-of-life measures deteriorated in the pazopanib group during the treatment period. CONCLUSION Pazopanib did not improve DFS as the primary end point compared with blinded placebo in patients with mRCC with NED after metastasectomy. In addition, there was a concerning trend favoring placebo in OS.
Risk Factors for Thyroid Dysfunction in Pregnancy: An Individual Participant Data Meta-Analysis
Osinga, J. , Liu, Yindi , Vafeiadi, Marina , Tao, Fangbiao , López‐Bermejo, Abel , Boucai, Laura , Hisada, Aya , Yoshinaga, Jun , Broeren, Maarten A.C., Itoh, Sachiko, Kishi, Reiko , Ashoor, Ghalia, Veltri, Flora, Lu, Xuemian , Taylor, Peter , Chatzi, Leda , Grineva, Elena , Ghafoor, Farkhanda, Pirzada, Amna, Kianpour, Maryam , Oken, Emily , Suvanto, Eila, Irizar, Amaia , Boelaert, Kristien , Brenta, Gabriela , Dhillon‐Smith, Rima , Dosiou, Chrysoula , Eaton, Jennifer L., Guan, Haixia , Nguyen, Caroline T. , Pop, Victor J.M. , Walsh, John P. , D’Alton, Mary E. , Carty, David , Delles, Christian , Alexander, Erik K. , Pearce, Elizabeth N. , Derakhshan, Arash , Korevaar, Tim I.M. , Osinga, Joris A J , Boucai, Laura , Feldt-Rasmussen, Ulla , Brenta, Gabriela , Guan, Haixia , Lee, Sun Y , Walsh, John P , Nelson, Scott McGill , Bliddal, Sofie , Pearce, Elizabeth N , Taylor, Peter N , López-Bermejo, Abel , Oken, Emily , Dosiou, Chrysoula , Männistö, Tuija , Vaidya, Bijay , Vrijkotte, Tanja G. M. , Mosso, Lorena , Bassols, Judit , Aminorroaya, Ashraf , Chen, Liangmiao , Brown, Suzanne J , Popova, Polina , Hattersley, Andrew T. , Rebagliato, Marisa , Galán, Isolina Riaño , Vrijheid, Martine , Delgado-Saborit, Juana María , Fernández‐Somoano, Ana , Santa‐Marina, Loreto , Maraka, Spyridoula , Morris, Lilah F. , Shan, Zhongyan , Guxens, Mònica , Nicolaides, Kypros H. , Visser, W. Edward , Nelson, Scott M. , Chaker, Layal , Richards, C. Sue , Peeters, Robin P. , Bliddal, Sofie , Huang, Kun , Poppe, Kris Gustave

Mayo Clinic

Thyroid® | March 28, 2024 | Volume: 34 | Issue: 5 | Pages: 646-658

10.1089/thy.2023.0646 | PMID 38546971 Get It

Background: International guidelines recommend targeted screening to identify gestational thyroid dysfunction. However, currently used risk factors have questionable discriminative ability. We quantified the risk for thyroid function test abnormalities for a subset of risk factors currently used in international guidelines. Methods: We included prospective cohort studies with data on gestational maternal thyroid function and potential risk factors (maternal age, body mass index [BMI], parity, smoking status, pregnancy through in vitro fertilization, twin pregnancy, gestational age, maternal education, and thyroid peroxidase antibody [TPOAb] or thyroglobulin antibody [TgAb] positivity). Exclusion criteria were pre-existing thyroid disease and use of thyroid interfering medication. We analyzed individual participant data using mixed-effects regression models. Primary outcomes were overt and subclinical hypothyroidism and a treatment indication (defined as overt hypothyroidism, subclinical hypothyroidism with thyrotropin >10 mU/L, or subclinical hypothyroidism with TPOAb positivity). Results: The study population comprised 65,559 participants in 25 cohorts. The screening rate in cohorts using risk factors currently recommended (age >30 years, parity ≥2, BMI ≥40) was 58%, with a detection rate for overt and subclinical hypothyroidism of 59%. The absolute risk for overt or subclinical hypothyroidism varied <2% over the full range of age and BMI and for any parity. Receiver operating characteristic curves, fitted using maternal age, BMI, smoking status, parity, and gestational age at blood sampling as explanatory variables, yielded areas under the curve ranging from 0.58 to 0.63 for the primary outcomes. TPOAbs/TgAbs positivity was associated with overt hypothyroidism (approximate risk for antibody negativity 0.1%, isolated TgAb positivity 2.4%, isolated TPOAb positivity 3.8%, combined antibody positivity 7.0%; p < 0.001), subclinical hypothyroidism (risk for antibody negativity 2.2%, isolated TgAb positivity 8.1%, isolated TPOAb positivity 14.2%, combined antibody positivity 20.0%; p < 0.001) and a treatment indication (risk for antibody negativity 0.2%, isolated TgAb positivity 2.2%, isolated TPOAb positivity 3.0%, and combined antibody positivity 5.1%; p < 0.001). Twin pregnancy was associated with a higher risk of overt hyperthyroidism (5.6% vs. 0.7%; p < 0.001). Conclusions: The risk factors assessed in this study had poor predictive ability for detecting thyroid function test abnormalities, questioning their clinical usability for targeted screening. As expected, TPOAb positivity (used as a benchmark) was a relevant risk factor for (subclinical) hypothyroidism. These results provide insights into different risk factors for gestational thyroid dysfunction.
Neuroinvasive West Nile Virus Infection in Immunosuppressed and Immunocompetent Adults
Mbonde, Amir A. , Gritsch, David , Harahsheh, Ehab , Kasule, Sabirah N, Hasan, Shemonti , Parsons, Angela, Zhang, Nan , Butterfield, Richard , Shiue, Harn , Norville, Kathryn , Reynolds, Jenna , Vikram, Holenarasipur R. , Chong, Brian W. , Grill, Marie , Norville, Kathryn A, Reynolds, Jenna L, Grill, Marie F, Vikram, Holenarasipur R. , Shiue, Harn J

Mayo Clinic

JAMA Network Open | March 28, 2024 | Volume: 7 | Issue: 3 | Pages: e244294

10.1001/jamanetworkopen.2024.4294 | PMID 38546642 Get It

Importance West Nile virus (WNV) is the leading cause of human arboviral disease in the US, peaking during summer. The incidence of WNV, including its neuroinvasive form (NWNV), is increasing, largely due to the expanding distribution of its vector, the Culex mosquito, and climatic changes causing heavy monsoon rains. However, the distinct characteristics and outcomes of NWNV in individuals who are immunosuppressed (IS) and individuals who are not IS remain underexplored. Objective To describe and compare clinical and radiographic features, treatment responses, and outcomes of NWNV infection in individuals who are IS and those who are not IS. Design, Setting, and Participants This retrospective cohort study used data from the Mayo Clinic Hospital system collected from July 2006 to December 2021. Participants were adult patients (age ≥18 years) with established diagnosis of NWNV infection. Data were analyzed from May 12, 2020, to July 20, 2023. Exposure Immunosuppresion. Main Outcomes and Measures Outcomes of interest were clinical and radiographic features and 90-day mortality among patients with and without IS. Results Of 115 participants with NWNV infection (mean [SD] age, 64 [16] years; 75 [66%] male) enrolled, 72 (63%) were not IS and 43 (37%) were IS. Neurologic manifestations were meningoencephalitis (98 patients [85%]), encephalitis (10 patients [9%]), and myeloradiculitis (7 patients [6%]). Patients without IS, compared with those with IS, more frequently reported headache (45 patients [63%] vs 18 patients [42%]) and myalgias (32 patients [44%] vs 9 patients [21%]). In contrast, patients with IS, compared with those without, had higher rates of altered mental status (33 patients [77%] vs 41 patients [57%]) and myoclonus (8 patients [19%] vs 8 patients [4%]). Magnetic resonance imaging revealed more frequent thalamic T2 fluid-attenuated inversion recovery hyperintensities in individuals with IS than those without (4 patients [11%] vs 0 patients). Individuals with IS had more severe disease requiring higher rates of intensive care unit admission (26 patients [61%] vs 24 patients [33%]) and mechanical ventilation (24 patients [56%] vs 22 patients [31%]). The 90-day all-cause mortality rate was higher in the patients with IS compared with patients without IS (12 patients [28%] vs 5 patients [7%]), and this difference in mortality persisted after adjusting for Glasgow Coma Scale score (adjusted hazard ratio, 2.22; 95% CI, 1.07-4.27; P = .03). Individuals with IS were more likely to receive intravenous immunoglobulin than individuals without IS (12 individuals [17%] vs 24 individuals [56%]), but its use was not associated with survival (hazard ratio, 1.24; 95% CI, 0.50-3.09; P = .64). Conclusions and Relevance In this cohort study of individuals with NWNV infection, individuals with IS had a higher risk of disease complications and poor outcomes than individuals without IS, highlighting the need for innovative and effective therapies to improve outcomes in this high-risk population.
Same-day Ileostomy Closure Discharge Reduces Costs Without Compromising Outcomes
Violante, Tommaso , Merchea, Amit , Stocchi, Luca , Moriarty, James P. , Violante, Tommaso , Ferrari, Davide , Borah, Bijan J. , Larson, David W.

Mayo Clinic

Annals of Surgery | March 28, 2024 | Volume: 280 | Issue: 6 | Pages: 973-978

10.1097/sla.0000000000006285 | PMID 38545779 Get It

Objective: This study aims to assess the costs of a same-day discharge (SDD) enhanced recovery pathway for diverting loop ileostomy (DLI) closure compared with a standard institutional enhanced recovery protocol. Background: Every year, 50,155 patients in the United States undergo temporary stoma reversal. While ambulatory stoma closure has shown promise, widespread adoption remains slow. This study builds on previous research, focusing on the costs of a novel SDD protocol introduced in 2020. Methods: A retrospective case-control study was conducted at Mayo Clinic, Rochester, Minnesota, and Mayo Clinic, Jacksonville, Florida, comparing patients undergoing SDD DLI closure from August 2020 to February 2023 to those in a matched cohort receiving standard inpatient enhanced recovery protocol. Patients were matched based on age, sex, american society of anesthesiologists score, surgery period, and hospital. Primary outcomes included direct hospitalization and additional costs in the 30 days postdischarge. Results: The SDD group (n = 118) demonstrated a significant reduction in median index episode hospitalization and 30-day postoperative costs compared with the inpatient group (n = 236), with savings of $4827 per patient. Complication rates were similar, and so were readmission and reoperation rates. Conclusions: Implementation of the SDD for DLI closure is associated with substantial cost savings without compromising patient outcomes. The study advocates for a shift towards SDD protocols, offering economic benefits and potential improvements in health care resource utilization.
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Saloner, Rowan , Staffaroni, Adam M. , Dammer, Eric B. , Johnson, Erik C. B. , Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Lago, Argentina Lario , Webb, Julia D, Kramer, Joel H. , Li, Jingyao , Sivasankaran, Rajeev , Seyfried, Nicholas T. , Yokoyama, Jennifer S. , Grinberg, Lea T. , Ljubenkov, Peter A. , Brushaber, Danielle , Considine, Ciaran , Day, Gregory S. , Faber, Kelley , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hales, Chadwick M. , Huey, Edward D. , Kornak, John , Lee, Suzee, Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Paulson, Henry L. , Petrucelli, Leonard , Ramos, Eliana Marisa , Rascovsky, Katya, Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Vandebergh, Marijne , Rosen, Howie, Boxer, Adam L. , Casaletto, Kaitlin B. , Staffaroni, Adam M , Hansson, Oskar , Sivasankaran, Rajeev , Yokoyama, Jennifer , Spina, Salvatore , Grinberg, Lea , VandeVrede, Lawren , Brushaber, Danielle , Day, Gregory S , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Galasko, Douglas , Geschwind, Daniel , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Lapid, Maria I. , Litvan, Irene , Mendez, Mario , Pascual, Belen , Roberson, Erik , Snyder, Allison , Tartaglia, Maria Carmela , Vandebergh, Marijne , Boeve, Brad , Paulson, Henry L , Dammer, Eric B

Mayo Clinic

No container title available | March 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4103685/v1 | PMID 38585969 Get It

Abstract The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN, MAPT) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Brahmania, Mayur , Kuo, Alexander , Tapper, Elliot B. , Völk, Michael , Vittorio, Jennifer , Ghabril, Marwan , Morgan, Timothy R. , Kanwal, Fasiha , Parikh, Neehar D. , Mehta, Shivang , Goldberg, David S. , Duarte‐Rojo, Andrés , Paredes, Angelo H. , Sahota, Amandeep , McElroy, Lisa M. , Thomas, Charlie, Aslam, Saima , Ramakrishnan, Sudha , Flynn, Mary M. , Volk, Michael L , Vittorio, Jennifer M , Mehta, Shivang , Winder, Scott , Im, Gene , Goldberg, David , Lai, Jennifer , Duarte-Rojo, Andres , Paredes, Angelo H , Patel, Arpan , Sahota, Amandeep , McElroy, Lisa M , Wall, Anji E , Malinis, Maricar , Aslam, Saima , Simonetto, Douglas A , Ufere, Nneka N , Ramakrishnan, Sudha , Ibrahim, Yasmin , Asrani, Sumeet K , Serper, Marina , Ghabril, Marwan S , Parikh, Neehar D , Kanwal, Fasiha , Martin, Paul B. , Winder, Gerald Scott , Lai, Jennifer C. , Patel, Arpan , Wall, Anji , Simonetto, Douglas A. , Asrani, Sumeet K. , Serper, Marina

Mayo Clinic

Hepatology | March 27, 2024 | Volume: 80 | Issue: 3 | Pages: 742-753

10.1097/hep.0000000000000870 | PMID 38536021 Get It

The liver transplantation (LT) evaluation and waitlisting process is subject to variations in care that can impede quality. The American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) developed quality measures and patient-reported experience measures along the continuum of pre-LT care to reduce care variation and guide patient-centered care. Following a systematic literature review, candidate pre-LT measures were grouped into 4 phases of care: referral, evaluation and waitlisting, waitlist management, and organ acceptance. A modified Delphi panel with content expertise in hepatology, transplant surgery, psychiatry, transplant infectious disease, palliative care, and social work selected the final set. Candidate patient-reported experience measures spanned domains of cognitive health, emotional health, social well-being, and understanding the LT process. Of the 71 candidate measures, 41 were selected: 9 for referral; 20 for evaluation and waitlisting; 7 for waitlist management; and 5 for organ acceptance. A total of 14 were related to structure, 17 were process measures, and 10 were outcome measures that focused on elements not typically measured in routine care. Among the patient-reported experience measures, candidates of LT rated items from understanding the LT process domain as the most important. The proposed pre-LT measures provide a framework for quality improvement and care standardization among candidates of LT. Select measures apply to various stakeholders such as referring practitioners in the community and LT centers. Clinically meaningful measures that are distinct from those used for regulatory transplant reporting may facilitate local quality improvement initiatives to improve access and quality of care.
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
Peipert, John Devin , Lee, Ju‐Whei , Shen, Shu-en, O’Connell, Nathaniel S. , Carlos, Ruth C. , Graham, Noah , Smith, Mary Lou , Gareen, Ilana F. , Raper, Pamela J., Weiss, Matthias , Kumar, Shaji , Cella, David , Peipert, John Devin , Zhao, Fengmin , Shen, Shu‐En , Ip, Edward H. , Rajkumar, S. Vincent , Gray, Robert J. , Wagner, Lynne I.

Mayo Clinic

JAMA Network Open | March 27, 2024 | Volume: 7 | Issue: 3 | Pages: e243854

10.1001/jamanetworkopen.2024.3854 | PMID 38536173 Get It

ImportanceThere is substantial interest in capturing cancer treatment tolerability from the patient’s perspective using patient-reported outcomes (PROs).ObjectiveTo examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events.Design, Setting, and ParticipantsThis prospective survey study was conducted from February to April 2023. Among participants in the ECOG-ACRIN E1A11 trial (a phase 3, parallel design trial conducted between 2013 and 2019), patients with newly diagnosed multiple myeloma were randomized to receive bortezomib (VRd) or carfilzomib (KRd) plus lenalidomide and dexamethasone as induction therapy. The GP5 item was administered at baseline (pretreatment) and at 1 month, 2.8 months, and 5.5 months postbaseline. Eligible participants included patients with newly diagnosed multiple myeloma treated at community oncology practices or academic medical centers in the US.ExposuresGP5 response options were “very much,” “quite a bit,” “somewhat,” “a little bit,” and “not at all.” Responses at each assessment while undergoing treatment (1 month, 2.8 months, and 5.5 months) were categorized as high adverse event bother (ie, “very much,” and “quite a bit”) and low adverse event bother (ie, “somewhat,” “a little bit,” or “not at all”). In addition, change from baseline to each assessment while undergoing treatment was calculated and categorized as worsening by 1 response category and 2 or more response categories.Main Outcome and MeasureETD due to adverse events (yes vs no) was analyzed using logistic regression adjusting for treatment group, performance status, gender, race, and disease stage.ResultsOf the 1087 participants in the original trial, 1058 (mean [SD] age 64 [9] years; 531 receiving VrD [50.2%]; 527 receiving KRd [49.8%]) responded to item GP5 and were included in the secondary analysis. A small proportion (142 patients [13.4%]) discontinued treatment early due to AEs. For those with high adverse-effect bother, GP5 while undergoing treatment was associated with ETD at 1 month (adjusted odds ratio [aOR], 2.20; 95% CI, 1.25-3.89), 2.8 months (aOR, 3.41; 95% CI, 2.01-5.80), and 5.5 months (aOR, 4.66; 95% CI, 1.69-12.83). Worsening by 2 or more response categories on the GP5 was associated with ETD at 2.8 months (aOR, 3.02; 95% CI, 1.64-5.54) and 5.5 months (aOR, 5.49; 95% CI, 1.45-20.76).Conclusions and RelevanceIn this survey study of the E1A11 trial, worse GP5 response was associated with ETD. These findings suggest that simple assessment of adverse-effect bother while receiving treatment is an efficient way to indicate treatment tolerability and ETD risk.
Case study of invalid to valid shift in cognitive performance following successful treatment of psychogenic nonepileptic seizure events
Drane, Daniel L. , Price, Michele E., Rush, Beth K., Blackmon, Karen , Okada, Noah , Shade, Taylor, Valentin, Edward, Vinson, Joseph, Rosen, Phyllis, Hewitt, Kelsey C. , Valentin, Edward, Loring, David W.

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | March 27, 2024 | Volume: 45 | Issue: 10 | Pages: 1024-1038

10.1080/13803395.2024.2335600 | PMID 38533868 Get It

Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium
Yarur, Andrés , Ungaro, Ryan C. , Huang, Katherine , Wang, Wenfei , Sasankan, Priya , Zulqarnain, Mir, Johnson, Amanda M. , Bader, Geoffrey , Kay, Carl , Costable, Nicholas , Dulaney, David , Fenster, Marc, Beniwal‐Patel, Poonam , Syal, Gaurav , Cohen, Benjamin L., Yarur, Andres J , Ungaro, Ryan , Loftus, Edward, Deepak, Parakkal , Patel, Anish A , Loftus, Edward V. , Pekow, Joel , Deepak, Parakkal

Mayo Clinic

Inflammatory Bowel Diseases | March 26, 2024 | Volume: 31 | Issue: 1 | Pages: 131-139

10.1093/ibd/izae058 | PMID 38531068 Get It

Abstract Background Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included in these trials do not represent the cohort of patients treated in the real world. In this study, we aimed to describe the effectiveness and safety of ustekinumab in a clinical cohort of patients with UC. Methods We performed a multicenter retrospective cohort study and included patients with active UC starting ustekinumab. Variables collected included demographics, clinical data, and disease activity (measured using partial Mayo score [PMS] and endoscopic Mayo score) at follow-up. The primary outcomes were cumulative rates of steroid-free clinical and biochemical remission (SFCBR), defined as a PMS &lt;2 while off steroids and a normal C-reactive protein and/or fecal calprotectin. Results A total of 245 patients met inclusion criteria. The median time of follow-up was 33 (interquartile range, 17-53) weeks, and 214 (87.3%) had previous exposure to a biologic and/or tofacitinib. Rates of SFCBR, clinical remission, and endoscopic remission at 6 and 12 months were 12.0% (n = 16 of 139), 29.0% (n = 71 of 175), and 18.0% (n = 7 of 39), and 23.8% (n = 15 of 63), 54.3% (n = 57 of 105), and 31.0% (n = 9 of 29), respectively. Non-Hispanic White race, higher baseline PMS, and the use of concomitant corticosteroids were independently associated with failure to achieve SFCBR. Of the 73 that were dose escalated, 28.4% did not respond, 49.3% experienced a benefit, and 21.6% achieved remission. Conclusions In a population enriched with refractory UC, ustekinumab was well tolerated and induced remission in a significant number of patients. Larger studies with a longer follow-up are warranted.